These results suggest that our spontaneous immunocompetent head and neck tumor model is useful for testing cancer therapeutics and that IL-13-PE could be a useful treatment regimen for inhibiting the growth of human HNSCC. The gene discussed is IL13; the disease is head and neck neoplasm.